Gilead Sciences, Inc. (GILD)
| Market Cap | 193.48B +28.4% |
| Revenue (ttm) | 30.46B +5.5% |
| Net Income | -3.24B |
| EPS | -2.61 |
| Shares Out | 1.24B |
| PE Ratio | n/a |
| Forward PE | 17.09 |
| Dividend | $3.28 (2.10%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 6,070,932 |
| Open | 156.47 |
| Previous Close | 157.19 |
| Day's Range | 155.76 - 157.65 |
| 52-Week Range | 114.02 - 160.51 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 160.19 (+2.66%) |
| Earnings Date | Oct 29, 2026 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $160.19, which is an increase of 2.66% from the latest price.
News
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme
HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporti...
Gilead to acquire IL-23R inhibitor program from PepStar Therapeutics
Gilead (GILD) Sciences announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a priva...
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead a...
Texas AG secures $45M settlement with Gilead
Texas Attorney General Ken Paxton secured $45M in a settlement with Gilead (GILD) Sciences to resolve claims that the company engaged in an illegal kickback scheme that improperly influenced prescript...
Gilead to present new clinical, real-world evidence across PBC, HDV
Gilead (GILD) Sciences will present new clinical and real-world evidence across primary biliary cholangitis, PBC, and chronic hepatitis delta virus, HDV, infection at The Liver Meeting 2026, hosted by...
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus ...
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Germany's BioNTech said on Thursday it had teamed up with Gilead Sciences to test its experimental cancer therapy in combination with the US drugmaker's approved treatment in patients with a form of...
BioNTech announces collaboration, supply agreement with Gilead
BioNTech (BNTX) announced a clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate sacituzum...
Gilead price target raised to $172 from $168 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $172 from $168 and keeps a Buy rating on the shares after the company announced results from the phase 2…
Gilead to present new data across HIV, antiviral research at IDWeek
Gilead (GILD) Sciences taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights in...
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 2...
Gilead's pill succeeds in mid-stage bowel disease trial
Gilead Sciences said on Monday its experimental once-daily pill reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October ...
The Big 3: MRK, GILD, XOM
The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a s...
Vir Biotechnology enters collaboration, license agreement with Gilead
Vir Biotechnology (VIR) announced a collaboration and license agreement with Gilead (GILD) to discover and engineer three novel PRO-XTEN dual-masked T-cell engager, TCE, development candidates targeti...
Gilead price target raised to $168 from $162 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $168 from $162 and keeps a Buy rating on the shares after updating estimates ahead of the company’s Q3 report.
Gilead price target raised to $126 from $123 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $126 from $123 and keeps a Sector Perform rating on the shares as part of a…
Gilead price target raised to $158 from $150 at Truist
Truist raised the firm’s price target on Gilead (GILD) to $158 from $150 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Gilead price target lowered to $163 from $165 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $163 from $165 and keeps an Overweight rating on the shares. The firm adjusted its models for its biopharma…
Gilead price target raised to $170 from $160 at JPMorgan
JPMorgan raised the firm’s price target on Gilead (GILD) to $170 from $160 and keeps an Overweight rating on the shares. The firm expects the company to report another strong…
Cognizant announces five-year extension of its work with Gilead Sciences
Cognizant (CTSH) announced a five-year extension of its work with Gilead Sciences (GILD). Under the agreement, Cognizant will support Gilead’s continued development of DevOps capabilities and the resp...
Nurix Therapeutics announces second research term extension with Gilead
Nurix Therapeutics (NRIX) announced that Nurix and Gilead (GILD) have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an...
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
Gilead put volume heavy and directionally bearish
Bearish flow noted in Gilead (GILD) with 6,354 puts trading, or 4x expected. Most active are Nov-26 140 puts and 10/9 weekly 146 puts, with total volume in those strikes…